Recent advances in understanding the metabolic alterations in cancer cells have shed light on how tumors fuel rapid growth by preferentially engaging biosynthetic pathways [1, 2] . Although cellular metabolic pathways are rich pickings for drug targets, pin-pointing enzymes that critically contribute to tumor metabolism is key to establishing a therapeutic window since most of meta bolic enzymes also play important roles in normal tissues.
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Two recent studies explored the landscape of tumor metabolism using diff erent approaches, yet both identifi ed the enzyme phosphoglycerate dehydrogenase (PHGDH) to be critical for the viability of a subset of breast cancer cells that overexpress this enzyme [3, 4] . Possemato and colleagues conducted an elegant in vivo shRNA drop-out screen to identify metabolic pathways that might be diff erentially required for the viability of cancer cells. Th e authors transduced a lentiviral shRNA library targeting 133 metabolic enzymes and metabolite transporters into the human breast cancer cell line MCF10DCIS.COM [3] . Th ese cells were then injected into mice to establish xenograft tumors. By analyzing which shRNAs dis appeared from the library in the tumors, they were able to infer several metabolic genes to be necessary for the growth of tumor cells in vivo. PHGDH is among the several genes identifi ed in this screen.
Locasale and colleagues homed in on PHGDH from a diff erent angle. By analyzing glucose fl ux in the transformed HEK293T cells, they found a high fl ux of glucose towards glycine production that can be attributed to the serine biosynthetic pathway [4] . PHGDH is the fi rst enzyme in this pathway that diverts glucose from glycolysis to serine production.
By analyzing cancer CGH and gene expression data, both groups noted that PHGDH is amplifi ed or overexpressed in a subset of melanoma and breast cancers. In breast cancer, elevated PHGDH is more frequently found in estrogen receptor-negative and basal-like tumors. Strikingly, whereas RNAi-mediated depletion of PHGDH has little eff ect on the viability of untransformed breast epithelial cells or breast cancer cells without PHGDH amplifi cation/overexpression, depleting PHGDH strongly inhibited the proliferation of a panel of breast cancer cells where PHGDH is amplifi ed or overexpressed. Th is latter group of cells thus exhibit functional addiction to PHGDH. Furthermore, using an inducible PHGDH shRNA in the breast cancer MDA-MB-468 cells (which carry PHGDH amplifi cation), Possemato and colleagues showed that depletion of PHGDH also inhibited tumor growth in vivo [3] .
PHGDH catalyzes the fi rst step in the serine biosynthetic pathway (Figure 1 ). Th is pathway diverts a relatively small fraction (<10%) of 3-phosphoglycerate from glycolysis to generate serine as well as equimolar amounts of reduced nicotinamide adenine dinucleotide and α-ketoglutarate. Indeed, Possemato and colleagues showed that two other enzymes in this pathway, PSAT1 and PSPH, also have higher expres sion in estrogen receptor-negative breast tumors, and RNAi knockdown of PSAT1 and PSPH selectively impaired the viability of breast cancer cells harboring PHGDH amplifi cation [3] .
So do tumor cells with high levels of PHGDH need more serine for growth? Here the answer becomes more complicated. Locasale and colleagues found higher levels of PHGDH were associated with higher serine production in melanoma cells and, conversely, that RNAi Abstract Exemplifi ed by the cancer cell's preference for glycolysis (the Warburg eff ect), altered metabolism has taken centerstage as an emerging hallmark of cancer. Charting the landscape of cancer metabolic addictions should reveal new avenues for therapeutic attack. Two recent studies found subsets of human melanoma and breast cancers to have high levels of phosphoglycerate dehydrogenase (PHGDH), a key enzyme for serine biosynthesis, and these cancer cells are dependent on PHGDH for their growth and survival. Tumors may thus harbor distinct metabolic alterations to support their malignancy, and targeting enzymes such as PHGDH might prove a viable therapeutic strategy in this scenario.
depletion of PHGDH decreased serine production [4] . On the other hand, Possemato and colleagues noted that breast cancer cells with high levels of PHGDH are resistant to serine withdrawal and their loss of viability upon PHGDH knock down cannot be rescued by supplemental serine. Instead, the depletion of PHGDH in breast cancer cells leads to a decrease in the level of α-ketoglutarate, a key biosynthetic precursor in the citric acid cycle. However, loss of α-ketoglutarate upon PHGDH depletion was not observed in melanoma cells by Locasale and colleagues. Th e same addiction to PHGDH therefore might manifest as distinct metabolite addictions -some cell lines might require serine, others α-ketoglutarate, and still others reduced nicotinamide adenine dinucleotide. Indeed, metabolic profi ling showed that the levels of many metabolites are altered upon PHGDH knockdown.
Intriguingly, PHGDH overexpression might directly promote oncogenesis. Using the MCF-10A breast epi thelial cell morphogenesis assay in 3D matrigel, Locasale and colleagues showed that overexpression of PHGDH in these cells increased their proliferation rate and disrupted the acinar structure of these cells. A change in cellular serine metabolism could thus directly lead to altered phenotypic behavior that favors transformation. Understanding how this happens would shed new light on the metabolic mechanisms of oncogenesis.
Th e studies by Possemato and colleagues and Locasale and colleagues strongly implicate PHGDH as an attractive drug target in the subset of tumors that amplify or overexpress this gene. As PHGDH-dependent serine biosynthesis operates in all cells, it would be important to determine whether a suffi cient therapeutic window exists. Congenital mutations in PHGDH have been documented in humans and result in serine defi ciency disorders. Th e main manifestation of this disorder is severe neurological symptoms of the central nervous system as serine does not cross the blood-brain barrier and consequently neurons and glial cells entirely rely on de novo serine synthesis [5] . Similar central nervous system disorders have been observed in PHGDH knockout mice [6] . Despite these manifestations, PHGDH inhibition remains a viable cancer therapeutic strategy for two reasons. First, a PHGDH inhibitor designed not to cross the blood-brain barrier would not interfere with serine homeostasis in the central nervous system, thus avoiding In vivo shRNA lethality screen and metabolomic profi ling independently identifi ed 3-phosphoglycerate dehydrogenase (PHGDH) to be essential in a subset of cancer cells that overexpress this enzyme. PHGDH plays a key role in serine biosynthesis, and cancer cells with high PHGDH activity might be addicted to this pathway for their viability. αKG, α-ketoglutarate; NADH, reduced nicotinamide adenine dinucleotide; PSAT1, phosphoserine aminotransferase 1; PSPH, phosphoserine phosphatase; TCA, tricarboxylic acid.
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